Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Austar Lifesciences Limited (6118.HK)
Shanghai, CN
Austar Lifesciences Limited functions as an investment holding company, delivering integrated engineering and technology solutions to pharmaceutical production facilities and research institutions globally, with a significant presence in Mainland China. Its business activities are structured across six primary divisions: liquid and bioprocessing systems; controlled environment and automated monitoring systems; powder and solid material handling systems; Good Manufacturing Practice (GMP) adherence services; life science expendables; and the brokerage and supply of pharmaceutical machinery. The company's product portfolio is extensive, including systems for pharmaceutical water, liquid preparation, and bioprocessing; powder and solid processing units; clean utility infrastructure; and advanced cleanroom technology. They also supply automated control and monitoring systems, freeze-dryers, sterile filling equipment, and visual inspection apparatus. Furthermore, Austar provides products for pharmaceutical contamination control, aseptic packaging and containment, biosafety and lab animal equipment and consumables, single-use bioprocess components, and offers holistic laboratory setup solutions. Beyond its product offerings, Austar Lifesciences extends a wide array of professional services, such as design and engineering, quality risk management, expert consultation, research and development assistance, process optimization, and digitalization strategies. The company also offers post-sale support, on-site services, system upgrades, facility relocation guidance, and comprehensive asset management. Additionally, it serves as an agent and distributor for pharmaceutical equipment, providing associated assembly and pre-assembly services. Established in 1991, Austar Lifesciences Limited is headquartered in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.27% | -2.50% | -2.50% | +0.00% | -18.75% | -10.34% | +13.04% | -57.38% | -92.57% | -40.91% | -78.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+2.0% Q4'25: +2.9% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+110.2% ★ Q4'25: +135.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+4.2% ★ Q4'25: +9.9% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+2.8% Q4'25: +2.6% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+3.3% ★ Q4'25: +6.0% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×4.71× Q4'25: 2.27× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2014 actual |
|---|---|
| Revenue |
679.75M
est: 534.08M (+27.3%)
|
| EBITDA |
91.97M
est: 24.68M (+272.7%)
|
| EBIT |
84.65M
est: 15.69M (+439.5%)
|
| Net Income |
65.19M
est: 57.68M (+13.0%)
|
| SGA |
122.41M
est: 86.61M (+41.3%)
|
| EPS |
0.17
est: 0.11 (+51.1%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-15 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-14 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 3/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 3/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 3/5 | 3/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 3/5 | 3/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 3/5 | 3/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kwok Keung | Founder, Chairman of the Board & Chief Executive Officer | 906.0K | male |
| Kin Hung | Executive Director | 891.0K | male |
| Ce Bian | Executive Director | 891.0K | male |
| Madam Ning Zhou | Executive Director | 891.0K | — |
| Madam Wang Wei | Senior Vice President | — | — |
| Madam Xiangdi Tang | Vice President of Corporate Development & Finance | — | — |
| Yuk Kiu Mak | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6118.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
